Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels

David H. Henry, MD, John Glaspy, MD MPH, Rosemary Anne Harrup, Moshe Mittelman, MD, Amy Zhou, MD, Hetty E. Carraway, MD MBA, Charles Bradley, PhD, Gopal Saha, MD, Pamela Bartels, Robert Leong, Peony Yu, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142499

Published: 2020

Journal Articles

Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)

David H. Henry, MD, John Glaspy, MD MPH, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, Moshe Mittelman, MD, Amy Zhou, MD, Charles Bradley, PhD, Gopal Saha, MD, Pamela Bartels, Leong Robert, Kin-Hung P Yu, MD

Blood (2019) 134 (Supplement_1): 843.

https://doi.org/10.1182/blood-2019-128714

Published: 2019

Journal Articles

A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

John Glaspy, MD, Tom Tang, MD, Dean Rutty, MSc, Xiaoqiang Yan, PhD, Igor Bondarenko, MD PhD, Dmitrii Krasnozhon, MD

Blood (2014) 124 (21): 1584.

https://doi.org/10.1182/blood.V124.21.1584.1584

Published: 2014

Journal Articles

High-Dose Vincristine Sulfate Liposome Injection (Marqibo ® ) Is Not Associated With Clinically Meaningful Hematologic Toxicity

Olivia R. Deitcher, John Glaspy, MD, Rene Gonzalez, MD, Takami Sato, Agop Bedikian, MD, Karen Segarini, Jeffrey A. Silverman, Ph.D., Steven R. Deitcher, MD

Blood (2013) 122 (21): 2676.

https://doi.org/10.1182/blood.V122.21.2676.2676

Published: 2013

Journal Articles

Current Practice In Diagnosis and Treatment of Chemotherapy-Induced Anemia In Five European Countries – A Patient Record Study

Yves Beguin, MD, PhD, Matti Aapro, MD, Carsten Bokemeyer, MD, John Glaspy, MD, Michael Hedenus, MD, Timothy James Littlewood, MD, FRCP, Heinz Ludwig, MD, Anders Österborg, MD, Daniell Mitchell, PhD

Blood (2010) 116 (21): 1512.

https://doi.org/10.1182/blood.V116.21.1512.1512

Published: 2010

Journal Articles

Patterns of Care in Patients with Chemotherapy Receiving Erythropoiesis Stimulating Agents (ESAs).

Arash Naeim, MD, Lyssa Friedman, RN, MPA, Eric Elkin, MPH, Sara Adams, MPH, Hema Viswanathan, PhD, Joel Kallich, PhD, John Glaspy, MD

Blood (2007) 110 (11): 964.

https://doi.org/10.1182/blood.V110.11.964.964

Published: 2007

Journal Articles

Early and Standard Intervention with Epoetin Alfa (PROCRIT®) 120,000 Units (U) Every Three Weeks (Q3W) in Patients with Cancer Receiving Chemotherapy - Results of a Planned Interim Analysis.

John Glaspy, MD, Victor Moyo, MD, Marc Kamin, MD, Francois E. Wilhelm, MD,PhD,MSc

Blood (2006) 108 (11): 3774.

https://doi.org/10.1182/blood.V108.11.3774.3774

Published: 2006

NARROW

Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels

Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)

A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

High-Dose Vincristine Sulfate Liposome Injection (Marqibo ® ) Is Not Associated With Clinically Meaningful Hematologic Toxicity

Current Practice In Diagnosis and Treatment of Chemotherapy-Induced Anemia In Five European Countries – A Patient Record Study

Patterns of Care in Patients with Chemotherapy Receiving Erythropoiesis Stimulating Agents (ESAs).

Early and Standard Intervention with Epoetin Alfa (PROCRIT®) 120,000 Units (U) Every Three Weeks (Q3W) in Patients with Cancer Receiving Chemotherapy - Results of a Planned Interim Analysis.

Email alerts

ASH Publications

American Society of Hematology

Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels

Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)

A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

High-Dose Vincristine Sulfate Liposome Injection (Marqibo ® ) Is Not Associated With Clinically Meaningful Hematologic Toxicity

Current Practice In Diagnosis and Treatment of Chemotherapy-Induced Anemia In Five European Countries – A Patient Record Study

Patterns of Care in Patients with Chemotherapy Receiving Erythropoiesis Stimulating Agents (ESAs).

Early and Standard Intervention with Epoetin Alfa (PROCRIT®) 120,000 Units (U) Every Three Weeks (Q3W) in Patients with Cancer Receiving Chemotherapy - Results of a Planned Interim Analysis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only